Exagen Inc. (XGN) Reports Q4 Loss, Beats Revenue Estimates

分组1 - Exagen Inc. reported a quarterly loss of $0.2 per share, consistent with the Zacks Consensus Estimate, and the same loss as the previous year [1] - The company posted revenues of $16.63 million for the quarter ended December 2025, exceeding the Zacks Consensus Estimate by 1.62% and showing an increase from $13.65 million year-over-year [2] - Exagen shares have declined approximately 44.4% since the beginning of the year, contrasting with the S&P 500's decline of 0.7% [3] 分组2 - The earnings outlook for Exagen is uncertain, with current consensus EPS estimates at -$0.15 for the coming quarter and -$0.48 for the current fiscal year [7] - The Zacks Industry Rank indicates that the Medical - Products sector is in the bottom 38% of over 250 Zacks industries, suggesting potential underperformance compared to higher-ranked industries [8] 分组3 - The estimate revisions trend for Exagen was unfavorable prior to the earnings release, resulting in a Zacks Rank 4 (Sell) for the stock, indicating expected underperformance in the near future [6] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]